CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

by Regina Jitschin, Domenica Saul, Martina Braun, Sehmus Tohumeken, Simon Völkl, Roman Kischel, Michael Lutteropp, Cedric Dos Santos, Andreas Mackensen, Dimitrios Mougiakakos
Published 2018-11-01

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

by Hauke Stamm, Leticia Oliveira-Ferrer, Eva-Maria Grossjohann, Jana Muschhammer, Vanessa Thaden, Franziska Brauneck, Roman Kischel, Volkmar Müller, Carsten Bokemeyer, Walter Fiedler, Jasmin Wellbrock
Published 2019-12-01

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.

by Kimberly H Harrington, Chelsea J Gudgeon, George S Laszlo, Kathryn J Newhall, Angus M Sinclair, Stanley R Frankel, Roman Kischel, Guang Chen, Roland B Walter
Published 2015-01-01